Evidence map›Paper›PMID 42633950›Full record

ArticleBasic & clinical pharmacology & toxicology2026

Acute Kidney Injury During Vancomycin Treatment in Adult Patients With Haematologic Malignancies: A Multicentre Retrospective Study.

Yuzhu Wang, Jie Li, Xingyun Hou, Ying Zhang, Chengchun Zuo, Xiaoqiang Ding, Xiaoyu Li, Qianzhou Lv, Hejin Lai, Kunming Pan

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Basic & clinical pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuzhu WangDepartment of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-7456-8980
Jie LiDepartment of Pharmacy, Tongji Hospital of Tongji University, Shanghai, China.
Xingyun HouDepartment of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-9364-3077
Ying ZhangDepartment of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.
Chengchun ZuoDepartment of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.
Xiaoqiang DingDepartment of Nephrology, Zhongshan Hospital Fudan University, Shanghai, China.
Xiaoyu LiDepartment of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.
Qianzhou LvDepartment of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.
Hejin LaiCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Shanghai, China.
Kunming PanDepartment of Pharmacy, Zhongshan Hospital Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-3907-2939

Funding

National Natural Science Foundation of China 82204520Natural Science Foundation of Fujian Province 2026J0011894Shanghai Municipal Health Commission 202240293Shanghai Municipal Health Commission 20244Y0101Shanghai 'Rising Stars of Medical Talent' Youth Development Program Youth Medical Talents-Clinical Pharmacist Program SHWSRS(2023)106
6 · The paper itself

Abstract

backgroundAcute kidney injury (AKI) during vancomycin treatment remains a rare occurrence in adult patients with haematological malignancies (HMs). The objective of this multicentre study was to investigate the incidence and risk factors for AKI during vancomycin treatment in patients with HM.

methodsThe present study examined patients who were admitted to hospital and receiving vancomycin therapy between 2009 and 2024 at three tertiary hospitals. The primary outcome was the incidence of AKI during vancomycin treatment.

resultsThe study comprised a total of 610 out of 982 patients. The incidence of AKI during vancomycin treatment among patients with HM was 13.0% (79/610). Multiple logistic regression analysis revealed that cardiac insufficiency (OR 3.305, 95% CI = 1.498-7.290, p = 0.003), chronic kidney disease (OR 5.074, 95% CI = 1.636-15.735, p = 0.005), hypoalbuminaemia (OR 2.930, 95% CI = 1.515-5.664, p = 0.001), concomitant spironolactone (OR 3.362, 95% CI = 1.586-7.290, p = 0.002) and chemotherapeutic drugs (OR 6.683, 95% CI = 2.025-22.051, p = 0.002) were independent risk factors for AKI during vancomycin treatment.

conclusionThe occurrence of AKI in adult patients with HM during vancomycin treatment is a prevalent issue and is associated with a number of clinical and treatment-related factors. HM patients with cardiac dysfunction, chronic kidney disease, hypoalbuminaemia or concomitant spironolactone, chemotherapeutic agents may have a higher risk of AKI during vancomycin treatment.

Indexed as

Acute Kidney InjuryAnti-Bacterial AgentsHematologic NeoplasmsVancomycinAdultAgedFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsAnti-Bacterial AgentsVancomycinacute kidney injuryadult patientshaematological malignancyrisk factorsvancomycin

Identifiers

PMID42633950
PMCPMC13500220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.